Side of LogoAETC National Resource Center HomeSide of LogoTop of BannerSpacerSpacer
AETC Only
Side of Banner
AETC Services and ContactsAETC Education and Training ResourcesSearchAETC National Resource Center Home
Spacer
Spacer
transparent gif
spacespaceClinical Manual > Complaints > Esophageal Problems
space
 CONTENTS
1Testing/ Assessment
2Health Maintenance
3ARV Therapy
4ARV Complications
5Complaints
6Diseases
7Pain and Palliative
8Neuropsychiatric
9Populations
10Resources
  
space

Clinical Manual for Management of the HIV-Infected Adult
2006 Edition

Section 5: Complaint-Specific Workups

Esophageal Problems

Chapter Contents
Background
Subjective
Objective
Assessment
Plan
References
space

Background

Esophageal problems in HIV-infected patients include difficulty swallowing (dysphagia) or midline retrosternal pain when swallowing (odynophagia). Pain may be diffuse throughout the esophagus or localized in specific areas.

Several conditions may cause esophageal problems. Of the infectious causes of dysphagia in HIV-infected patients, Candida is the most common (50-70%). Drug-induced dysphagia, gastroesophageal reflux disease (GERD), vomiting, and hiatal hernia can also cause esophagitis. Less commonly, neoplasm or another cause of stricture may produce symptoms. Neuromuscular or neurological causes may be seen in patients with advanced AIDS.

If untreated, esophageal problems may result in esophageal ulcers, scarring of the esophagus, dehydration, and weight loss.

S: Subjective

The patient may complain of difficulty swallowing, a feeling of something being "stuck in the throat," retrosternal pain when eating, "hiccups," indigestion ("heartburn"), acid reflux, nausea, vomiting, or abdominal pain.

The history should include the following:

O: Objective

Include the following in the physical examination:

A: Assessment

Common causes of esophageal problems are as follows:

Less common causes of esophageal problems include:

P: Plan

Diagnostic Evaluation

Diagnosis often can be made on clinical grounds; in this case, empiric treatment may be initiated (see below). If the diagnosis is unclear, consider endoscopy or radiographic imaging (eg, CT or barium swallow).

Treatment

Determine whether the patient is able to swallow pills before giving oral medications. If pills are not tolerated, the patient may need liquids or troches.

For patients with severe oral or esophageal pain, viscous lidocaine 1% 5-10 mL 2-4 times daily (with swallowing precautions) or Magic Mouthwash (viscous lidocaine 1%, tetracycline, Benadryl, and nystatin compounded 1:1:1:1) may be tried.

Other treatments may depend on the underlying cause:

  • Esophageal candidiasis: Fluconazole (Diflucan) is the drug of choice. If symptoms resolve within 7-10 days, no further testing is required. See chapter Candidiasis, Oral and Esophageal for more options and for dosing.
  • Medication-related: Remove the offending drug(s), and institute a trial of H2 blockers or proton pump inhibitors (PPIs) as appropriate.*
  • Food-related: Modify the diet and institute a trial of H2 blockers or PPIs as appropriate.*
  • GERD: For nonpharmacologic treatment, in cases of obesity, counsel patients to lose weight, stop smoking, elevate the head of the bed, eat smaller meals, avoid eating food 2-3 hours before bedtime, and reduce fat in the diet to ≤30% of calorie consumption.
  • "Heartburn" or reflux: Patients whose primary symptoms are more typical of "heartburn" or reflux, especially those with a history of GERD, should receive a trial of H2 blockers or PPIs as appropriate.* Some patients will require both an H2 blocker and a PPI to control symptoms. Reevaluate after 1-2 weeks; if symptoms are controlled, treat for 8 weeks, then reduce the dosage to the lowest effective amount. Patients may require maintenance therapy for an indefinite period because of the high likelihood of recurrence.
  • CMV: Treat with anti-CMV medications (eg, oral valganciclovir). See chapter Cytomegalovirus Disease for details.
  • HSV: Treat with antiviral medications including acyclovir (Zovirax), famciclovir (Famvir), or valacyclovir (Valtrex). See chapter Herpes Simplex, Mucocutaneous.
  • Aphthous ulcers: These may respond to oral corticosteroids (prednisone 40 mg/d for 7-14 days, tapered to 10 mg per week for 4 weeks; a shorter course may be effective for small ulcers). Alternatively, a combination of H2 blockers* and sucralfate (Carafate) may be effective. In some circumstances, thalidomide 200 mg every 24 hours may be used. (Note: Thalidomide is teratogenic, and women of childbearing potential are not candidates for this therapy unless the benefits clearly outweigh the risks and appropriate prevention of pregnancy is undertaken.) Up to 40-50% of patients with aphthous ulcers experience relapse and require repeat treatment.
  • Neoplastic disease requires referral to an oncologist.

* Caution: PPIs and H2 blockers interfere with the absorption of atazanavir. PPIs are contraindicated in patients taking atazanavir (Reyataz). H2 blockers may be used cautiously in patients on ritonavir-boosted atazanavir, if they are separated from the atazanavir doses by 12 hours.

Esophageal conditions that do not resolve with treatment require referral to a GI specialist for diagnostic endoscopy, with biopsy and brushing for histopathology and cultures as appropriate.

Diet

It is important that patients maintain adequate caloric intake, preferably with foods and liquids that can be swallowed easily. Nutritional supplements along with soft, bland, high-protein foods are recommended. Refer to nutritionist as needed.

References

space
space
  space

Copyright 2006, the AIDS Education & Training Centers National Resource Center, unless otherwise noted. All rights reserved. Email webmaster@aidsetc.org with questions, comments, or problems. See disclaimer for usage guidelines.